Hutchmed to present cancer study data at AACR meeting

HONG KONG - Hutchmed (China) Limited (NASDAQ/AIM:HCM; HKEX:13) has announced that it will present new and updated data from several studies at the American Association for Cancer Research (AACR) Annual Meeting 2025, set to take place from April 25-30 in Chicago, Illinois. The studies focus on compounds discovered by Hutchmed, including savolitinib, fruquintinib, and surufatinib.

The company will share findings from both sponsored and investigator-initiated studies. Among the highlights are results from the SAVANNAH study, which evaluates the clearance of plasma EGFRm in patients with non-small cell lung cancer (NSCLC) treated with savolitinib in combination with osimertinib. This late-breaking poster session is scheduled for Wednesday, April 30. Additionally, a Phase I study to determine brain exposure of savolitinib using positron-emission tomography in healthy volunteers will be presented on Tuesday, April 29.

Investigator-initiated studies include a multi-cohort study of treatment regimens for metastatic colorectal cancer (mCRC), with a subgroup analysis of sequential therapy between fruquintinib and regorafenib presented on Monday, April 28. Other studies involving fruquintinib and surufatinib in various combinations and settings will also be discussed during the meeting.

Savolitinib, a MET tyrosine kinase inhibitor, is jointly developed by Hutchmed and AstraZeneca (NASDAQ:AZN) and is approved in China for the treatment of NSCLC with MET exon 14 skipping alterations. The drug is under clinical development for multiple tumor types. The combination of savolitinib and TAGRISSO® (osimertinib) has been studied extensively, with the SACHI trial in China and the global SAFFRON trial among others. The SACHI trial has met its primary endpoint of progression-free survival and has been granted Breakthrough Therapy Designation and Priority Review status in China as of December 2024.

Hutchmed is a biopharmaceutical company focused on the discovery, development, and commercialization of cancer and immunological disease therapies. It has brought several drug candidates from in-house discovery to patients worldwide, with three medicines marketed in China and approvals in other countries, including the US, Europe, and Japan.

This news article is based on a press release statement and contains forward-looking statements regarding the potential therapeutic benefits of Hutchmed’s compounds and their clinical development. The release emphasizes the company’s commitment to addressing cancer treatment needs and its ongoing efforts in research and development.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.